Has Biotech Met Its Moment?
A surge in private market investment has Fools wondering: is it time to bet bigger on biotech? Tim Beyers and Karl Thiel discuss: - The rise in biotech funding from VCs and wealthy individuals. - The key attributes of an investable biotech. - Which is the better biotech: Viking Therapeutics or Eli Lilly? Companies…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from Motley Fool Hidden Gems Investing
See all episodes →Paramount + Warner Bros.: The $110 Billion Bet That Could Reshape Streaming
Facing Our Investing Fears
Why the Wealthiest People in the Room Are Often the Most Miserable — And What to Do About It
Similar episodes from other shows
More like Motley Fool Hidden Gems Investing →
#303: The AI Stocks No One is Talking About: Biotech Boom
Longevity: Can We Add Another 30 Years? | The Decade Ahead
This sector is booming - but have investors missed the boat?
A Biotech Breakdown and Two Sides of the Streaming Wars
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.